incomplete cross-resistance among cisplatin , dacarbazine , dibromodulcitol , ifosfamide , methyl-ccnu , mitomycin c , and phm has been observed after sequential drug exposures in clinical trials and was confirmed by simultaneous drug exposures in this panel of melanoma xenografts .
C0010927
dacarbazine
C0025202
xenografts